Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.76 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 5/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.47 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | STK4 | Q13043 | 1/20 | 0.46 |
| ▸ | STK3 | Q13188 | 1/20 | 0.46 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29889392 | 1.00 | PIK3CA (0.76) | PIK3CAMAPK13ALDH1A1KMOPRMT5 | |
| SCHEMBL1255470 | 0.86 | PIK3CA (1.00) | PIK3CAMAPK13ALDH1A1KMOPRMT5 | |
| SCHEMBL4309526 | 0.86 | PRKD1 (0.60) | PIK3CAALDH1A1PRMT5PRKD3PRKD1 | |
| SCHEMBL12639899 | 0.85 | PIK3CA (0.76) | PIK3CAMAPK13ALDH1A1KMOPRMT5 | |
| SCHEMBL1516927 | 0.85 | PIK3CA (0.76) | PIK3CAMAPK13ALDH1A1KMOPRMT5 | |
| SCHEMBL19160077 | 0.85 | PIK3CA (0.76) | PIK3CAMAPK13ALDH1A1KMOPRMT5 | |
| Hydrochloric Acid SCHEMBL15819749 | 0.85 | PIK3CA (0.97) | PIK3CAMAPK13ALDH1A1KMOPRMT5 | |
| SCHEMBL7692421 | 0.85 | MAPK13 (0.60) | PIK3CAMAPK13POLBNPC1MAPK14 | |
| SCHEMBL30290310 | 0.84 | PRKD3 (0.62) | PIK3CAALDH1A1PRMT5PRKD3PRKD1 | |
| Lithium Ion SCHEMBL31706550 | 0.84 | PIK3CA (0.74) | PIK3CAMAPK13ALDH1A1KMOPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672952-B1 | BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | claimed |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | claimed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | claimed |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | disclosed |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | disclosed |
| WO-2020243459-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | disclosed |
| US-20180148440-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2018-05-31 | — | — | US | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| EP-3174868-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | Nuevolution A/S (DK) | 2017-06-07 | — | — | EP | disclosed |
| US-7838676-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-11-23 | — | — | US | disclosed |
| CN-101796038-A | Oxazole tyrosine kinase inhibitors | SAREUM LTD | 2010-08-04 | — | — | CN | disclosed |
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| US-20070173521-A1 | Beta-secretase modulators and methods of use | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | disclosed |
| CN-1319092-A | Benzamide derivatives and their use as cytokine inhibitors | ASTRAZENECA AB (SE) | 2001-10-24 | — | — | CN | disclosed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148440-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, SLC8B1, P2RX1 | PIK3CA 1842/4885MAPK13 3351/4885ALDH1A1 1745/4885 |
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPKAPK3 | PIK3CA 579/4885MAPK13 38/4885ALDH1A1 1895/4885 |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | PIK3CA 93/4885MAPK13 2863/4885ALDH1A1 1065/4885 |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | PIK3CA 343/4885MAPK13 3024/4885ALDH1A1 617/4885 |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | BRD4, BRD3, BRDT | PIK3CA 1016/4885MAPK13 1590/4885ALDH1A1 3848/4885 |
| US-10752640-B2 | Compounds active towards bromodomains | BRD4, BRD3, BRDT | PIK3CA 1016/4885MAPK13 1590/4885ALDH1A1 3848/4885 |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | PIK3CA 4173/4885MAPK13 1957/4885ALDH1A1 2196/4885 |
| US-20070173521-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | PIK3CA 469/4885MAPK13 4644/4885ALDH1A1 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.